Beta-Aminoisobutyric Acid → Cryptophycin 28

HRID 618580ノート

反応式

HRID 618580 の反応式
[OH:1][CH:2]([CH:9](C)[CH:10](O)[CH:11](O)[C:12]1[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=1)[CH2:3][CH:4]=[CH:5][C:6]([OH:8])=O.[Cl:21][C:22]1[CH:23]=[C:24]([CH:31]=[CH:32][C:33]=1[O:34][CH3:35])[CH2:25][C@@H:26]([C:28]([OH:30])=O)[NH2:27].[NH2:36][CH2:37][CH:38]([CH3:42])[C:39]([OH:41])=[O:40].[C:43](O)(=[O:50])[CH:44]([CH2:46][CH:47]([CH3:49])[CH3:48])O.C[C@H]1C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@@H]([C@H]2O[C@@H]2C2C=CC=CC=2)C)CC=CC(=O)N[C@H](CC2C=CC(OC)=C(Cl)C=2)C(=O)NC1.CC1C(=O)OC(CC(C)C)C(=O)OC(C(C2OC2C2C=CC=CC=2)C)CC=CC(=O)NC(CC2C=CC(OC)=C(Cl)C=2)C(=O)NC1.C[C@H]1C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@@H](/C=C/C2C=CC=CC=2)C)CC=CC(=O)N[C@H](CC2C=CC(OC)=C(Cl)C=2)C(=O)NC1.C[C@H]1C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@@H](/C=C/C2C=CC=CC=2)C)CC=CC(=O)N[C@H](CC2C=CC(OC)=CC=2)C(=O)NC1.C[C@@H]1[C@@H](O)[C@H](C2C=CC=CC=2)O[C@H]1C/C=C/C(N[C@@H](C(NC[C@H](C(OC)=O)C)=O)CC1C=CC(OC)=C(Cl)C=1)=O>CO>[CH3:42][C@H:38]1[C:39](=[O:41])[O:40][C@@H:44]([CH2:46][CH:47]([CH3:49])[CH3:48])[C:43](=[O:50])[O:1][C@H:2]([CH2:9]/[CH:10]=[CH:11]/[C:12]2[CH:13]=[CH:14][CH:15]=[CH:16][CH:17]=2)[CH2:3][CH:4]=[CH:5][C:6](=[O:8])[NH:27][C@H:26]([CH2:25][C:24]2[CH:31]=[CH:32][C:33]([O:34][CH3:35])=[C:22]([Cl:21])[CH:23]=2)[C:28](=[O:30])[NH:36][CH2:37]1

参加物

11

反応物 9

HCID 64956Beta-Aminoisobutyric AcidHCID 92779(+-)-2-Hydroxyisocaproic acidHCID 5468287(13E)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[1-(3-phenyloxiran-2-yl)ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone6 回HCID 6438401Cryptophycin4 回HCID 9985532Cryptophycin 62 回HCID 10077879Cryptophycin 34 回HCID 538202503-Chloro-O-methyl-L-tyrosineHCID 540066555,7,8-Trihydroxy-6-methyl-8-phenyl-2-octenoic acidHCID 101025283Cryptophycin 43 回

生成物 1

HCID 10508182Cryptophycin 28

試薬・触媒・溶媒 1

HCID 887Methanol溶媒2 回

実験手順

[α]D +65.6°(MeOH, c 0.93); UV (MeOH) λmax (ε) 204 (48000), 230 (19300), 248 (18700), 280 (3400); IR (neat) νmax 3413, 3270, 2958, 1745, 1726, 1665, 1504, 1258, 1197, 1175, 1066, 694 cm-1 ; EIMS m/z (rel intensity) 624/626 (3.0/1.3), 412/414 (70/24), 280/282(13/6), 213 (100), 195/197 (86/40); high resolution EIMS m/z 624.2626 (calcd for C34H41ClN2O7, -2.4 mmu error); 1H NMR(CDCl3) amino or hydroxy acid unit δ (carbon position, multiplicity; J in Hz) 5-hydroxy-8-phenyl-2,7-octadienoic acid (A) 5.78 (2, d; 15.6), 6.71(3, ddd; 15.6, 9.9 and 5.4), 2.40 (4, m), 2.53 (4, m), 5.17 (5, m), 2.53 (6-H2, br t; 6.7), 6.07 (7, dt; 15.8 and 7.4), 6.44 (8, d; 15.8), 7.27-7.38 (10/11/13/14, m), 7.22 (12, m); 3-chloro-4-methoxyphenylalanine (B) 4.82 (2, m), 5.72 (2-NH, d; 8.5), 3.04 (3, dd; 14.5 and 7.2), 3.14 (3, dd; 14.5 and 5.4), 7.22 (5, d; 2.0), 3.87 (7-OMe, s), 6.84 (8, d; 8.5), 7.08 (9, dd; 8.5 and 2.0); 3-amino-2-methylpropionic acid (C) 2.72 (2, m), 1.21 (2-Me, d; 7.2), 3.29 (3, dt; 13.5 and 7.0), 3.49 (3, ddd; 13.5, 4.9 and 3.8), 6.97 (3-NH, br t; 5.6); leucic acid (D) 4.82 (2, m), 1.40 (3, m), 1.62 (3, m), 1.62 (4, m), 0.76 (4-Me, d; 6.3), 0.74 (5, d; 6.3); 13C NMR (CDCl3) unit δ (carbon position) A 165.4 (1), 125.2 (2), 141.2 (3), 38.5 (4), 73.5 (5), 38.6 (6), 124.1 (7), 133.8 (8), 136.7 (9), 126.1 (10/14), 128.6 (11/13), 127.6 (12); B 170.9 (1), 53.6 (2), 35.1 (3), 129.8 (4), 131.0 (5), 122.4 (6), 154.0 (7), 56.1 (7-OMe), 112.3 (8), 128.4 (9); C 175.6 (1), 38.3 (2), 14.0 (2-Me), 41.2 (3), D 170.9 (1), 71.6 (2), 39.6 (3), 24.5 (4), 21.5 (4-Me), 22.6 (5).

出典と根拠

ORDレコード
ord-4d15a1bf9d7749888450034cd506e324
出典データセット
uspto-grants-1999_09
特許番号
US05952298

反応ノート

読み込み中…